Movement Disorders

The chief training and education officer at the Parkinson’s Foundation detailed the challenges in disseminating educational materials to the clinical community that could have impacts on Parkinson disease care. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending February 4, 2023. [WATCH TIME: 4 minutes]

The list of women's contributions to the field of medicine is a long one, encompassing the hard work of hundreds of individuals. To highlight some of these pioneers, NeurologyLive® has compiled a timeline of 10 of the moments that matter in the history of women in medicine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 3, 2023.

The chief training and education officer at the Parkinson’s Foundation discussed the importance of educating healthcare professionals on different specialists that play a role in Parkinson disease management. [WATCH TIME: 2 minutes]

Treatment with deep brain stimulation resulted in improvements in mean motor scores, reductions levodopa equivalent dosage, and a decrease in neuropsychiatric features.

The chief training and education officer at the Parkinson’s Foundation provided perspective on the vast types of medical professionals who can learn from the organization’s new education series. [WATCH TIME: 4 minutes]

Branaplam, an mRNA splicing modifier, joins the many unsuccessful agents for Huntington disease as biopharma continues to be challenged with trial holds and failures.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.

The chief training and education officer at the Parkinson’s Foundation provided perspective on a recently launched online program aimed at educating healthcare professionals. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Richard Williamson, MD, FAANS, a neurosurgeon at Allegheny Health Network, provided commentary on the explosion of technology in neurosurgery and how exoscopes ease the process.

Neurology News Network for the week ending January 28, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 27, 2023.

Take a look at 5 of the most-anticipated FDA pending approvals expected in 2023 that neurological researchers and clinicians should keep an eye out on.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]

After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.

Going forward, the company must provide safety and steady-state pharmacokinetic data on the 200 mg dose of IKT-148009, as well as continued measurement of visual acuity and examination of the cornea and lens.

Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.

The phase 3 KINECT-HD study, which showed statistically significant differences from placebo in Total Maximal Chorea score, served as one of the main parts to valbenazine’s supplemental new drug application.

KM-819, a potent inhibitor of FAF1, a key regulatory protein in cell death pathways, is currently being assessed in a 2-part trial, with results expected to help guide a future 24-month study.

Similar to results at 24-months, findings showed improvements in patient outcomes with the SCS System including quality of life, functional ability, mood, and sleep.

Here's some of what is coming soon to NeurologyLive® this week.